Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Mier

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Cytokine|September 1, 1992
Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humansE V Granowitz, R Porat, J W Mier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinomaM B Atkins, J Sparano, R I Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinomaJ S Du Bois, E G Trehu, J W Mier, et al.
Blood|November 15, 1993
Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humansE V Granowitz, R Porat, J W Mier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.
Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1996
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimeraE G Trehu, J W Mier, J S Dubois, et al.
British Journal of Cancer|January 17, 2013
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenograftsX Wang, L Zhang, A O'Neill, et al.
Blood|October 25, 2001
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosisA Kaser, G Brandacher, W Steurer, et al.
American Journal of Hematology|August 1, 1987
Malignant granular lymphoproliferation after Epstein-Barr virus infection: partial immunologic reconstitution with interleukin-2F R Aronson, R A Dempsey, M Allegretta, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Cytokine|September 1, 1992
Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humansE V Granowitz, R Porat, J W Mier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinomaM B Atkins, J Sparano, R I Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinomaJ S Du Bois, E G Trehu, J W Mier, et al.
Blood|November 15, 1993
Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humansE V Granowitz, R Porat, J W Mier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.
Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1996
Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimeraE G Trehu, J W Mier, J S Dubois, et al.
British Journal of Cancer|January 17, 2013
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenograftsX Wang, L Zhang, A O'Neill, et al.
Blood|October 25, 2001
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosisA Kaser, G Brandacher, W Steurer, et al.
American Journal of Hematology|August 1, 1987
Malignant granular lymphoproliferation after Epstein-Barr virus infection: partial immunologic reconstitution with interleukin-2F R Aronson, R A Dempsey, M Allegretta, et al.
Pageof 9